CoV-2 Spike (800-1000)
CoV 2019 Spike Protein is >90% pure as determined SDS-PAGE.
Description
The E.Coli derived recombinant protein contains the Coronavirus 2019 Spike (800-1000 a.a.) immunodominant regions, fused to 6xHis tag at C-terminal.
Product Specs
In December 2019, a novel coronavirus, designated as 2019-nCoV, emerged in Wuhan, China, causing viral pneumonia. The virus was initially linked to a seafood market.
Genetic analysis revealed that 2019-nCoV shares a high degree of similarity (87%) with a bat-derived SARS-like coronavirus identified in 2018. This similarity extends to the receptor-binding domain (RBD) structure, suggesting that 2019-nCoV might utilize the ACE2 receptor in humans, similar to the 2018 SARS-CoV.
While bats are suspected to be the natural reservoir of 2019-nCoV, an intermediate animal host, potentially present at the seafood market, is also suspected. Research suggests that 2019-nCoV might have arisen from recombination events between a bat coronavirus and another unknown coronavirus, particularly in the spike glycoprotein region.
This product consists of the immunodominant portion of the Coronavirus 2019 Spike protein (amino acids 800-1000), produced in E. coli and purified. A 6xHis tag is attached to the C-terminus to facilitate purification and detection.
The CoV 2019 Spike Protein solution is provided at a concentration of 1 mg/ml in a phosphate-buffered saline (PBS) solution.
The CoV 2019 Spike Protein is shipped in insulated packaging with ice packs to maintain a low temperature. Upon receiving the product, it should be stored at -20 degrees Celsius (-4 degrees Fahrenheit) to preserve its quality and stability.
The purity of the CoV 2019 Spike Protein is greater than 90%, as determined by SDS-polyacrylamide gel electrophoresis (SDS-PAGE) analysis.
Product Science Overview
The Coronavirus 2019 Spike (800-1000 a.a.) Recombinant is a segment of the spike protein from the SARS-CoV-2 virus, which is responsible for the COVID-19 pandemic. This recombinant protein is used extensively in research and diagnostic applications to understand the virus’s behavior and develop therapeutic interventions.
The spike (S) protein of SARS-CoV-2 is a transmembrane protein that plays a crucial role in the virus’s ability to infect host cells. It is composed of two subunits, S1 and S2. The S1 subunit contains the receptor-binding domain (RBD), which binds to the host cell receptor ACE2, while the S2 subunit facilitates the fusion of the viral and host cell membranes .
The segment from amino acids 800 to 1000 is part of the S2 subunit. This region is critical for the conformational changes required for membrane fusion, making it a key target for neutralizing antibodies and vaccine development .
Recombinant proteins are produced by inserting the gene encoding the protein of interest into an expression system, such as bacteria, yeast, or mammalian cells. For the Coronavirus 2019 Spike (800-1000 a.a.) Recombinant, the gene segment corresponding to amino acids 800 to 1000 of the spike protein is cloned into an expression vector and introduced into a suitable host cell line .
The host cells then produce the recombinant protein, which is subsequently purified using techniques like affinity chromatography. The purified protein can be used in various applications, including structural studies, vaccine development, and diagnostic assays .
- Vaccine Development: The spike protein, including the 800-1000 a.a. segment, is a primary target for vaccine development. Vaccines aim to elicit an immune response against this protein, preventing the virus from entering host cells .
- Diagnostic Assays: Recombinant spike proteins are used in serological assays to detect antibodies against SARS-CoV-2 in patient samples. These assays help determine past infection and immunity levels in the population.
- Therapeutic Research: Understanding the structure and function of the spike protein aids in the development of antiviral drugs and monoclonal antibodies that can neutralize the virus.
